Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$31.19
$0.40(1.28%)
At close: 4:00 PM EDT
$31.19
$0.40(1.28%)
Day’s Range― - ―
52-Week Range$16.10 - $33.07
Previous Close$31.59
Volume994.73K
Average Volume (3M)1.23M
Market Cap
$2.04B
Enterprise Value$2.16K
Total Cash (Recent Filing)$152.63M
Total Debt (Recent Filing)$26.97M
Price to Earnings (P/E)26.2
Beta0.55
Next Earnings
Oct 29, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding76,726,800
10 Day Avg. Volume995,371
30 Day Avg. Volume1,230,805
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside5.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.28
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained high operating cash flow and FCF provide durable financial flexibility. Strong cash conversion funds reinvestment, share repurchases and working capital, reducing reliance on external financing and supporting multi‑year execution of growth initiatives even if revenue growth moderates.
Conservative Balance SheetExtremely low leverage and ample liquidity materially lower solvency risk. With minimal debt and sizable cash balances, the company can absorb cyclical utilization swings, invest in platform expansion, pursue tuck‑ins or return capital without threatening operations, a durable competitive advantage.
Scale And Improving ProfitabilityMulti‑year revenue scale and expanding margins indicate structural operating leverage. Revenue grew materially from prior years and management has maintained healthy adjusted EBITDA margins, implying the business model is maturing toward steadier profitability as utilization and care management efficiencies persist.
Bears Say
Moderating Growth & SeasonalitySeasonal and utilization variability reduce near‑term predictability of utilization‑driven revenue and complicate guidance. For a benefits model tied to member procedures, persistent seasonal dips can delay revenue recognition, strain short‑term cash flow timing and increase volatility in 2–6 month planning horizons.
Moderate Gross MarginsRelatively modest gross margins limit the buffer for funding growth, absorbing provider cost inflation, and expanding sales/marketing investments. In an active competitive market, limited gross margin headroom constrains pricing flexibility and could compress operating profitability if utilization or negotiated rates deteriorate.
New Channels Have Long Lead TimesStrategic initiatives (fully insured product, broker distribution) are medium‑to‑long‑term, so near‑term revenue upside is limited. Execution risk and delayed throughput mean management must rely on existing channels to drive growth while competitors pursue similar expansion, prolonging the timeline to diversify revenue sustainably.
Progyny News
PGNY FAQ
What was Progyny, Inc.’s price range in the past 12 months?
Progyny, Inc. lowest stock price was $16.10 and its highest was $33.06 in the past 12 months.
What is Progyny, Inc.’s market cap?
Progyny, Inc.’s market cap is $2.04B.
When is Progyny, Inc.’s upcoming earnings report date?
Progyny, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 77 days.
How were Progyny, Inc.’s earnings last quarter?
Progyny, Inc. released its earnings results on Aug 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.005.
Is Progyny, Inc. overvalued?
According to Wall Street analysts Progyny, Inc.’s price is currently Undervalued.
Does Progyny, Inc. pay dividends?
Progyny, Inc. does not currently pay dividends.
What is Progyny, Inc.’s EPS estimate?
Progyny, Inc.’s EPS estimate is 0.32.
How many shares outstanding does Progyny, Inc. have?
Progyny, Inc. has 76,726,800 shares outstanding.
What happened to Progyny, Inc.’s price movement after its last earnings report?
Progyny, Inc. reported an EPS of $0.34 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went down -6.984%.
Which hedge fund is a major shareholder of Progyny, Inc.?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (5.80% Upside)
$33.00 (5.80% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 872.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $372.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.93%
Trailing 12-Months
Company Description
Progyny, Inc.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
PGNY Company Deck
PGNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong financial and operational positives: record quarterly results, margin expansion, robust operating cash flow ($201M TTM), a clean balance sheet, sizable share repurchases, and meaningful early sales momentum with confidence to add 1M+ lives. The primary negatives were a slightly more pronounced summer seasonality that tempered near-term visibility and required modest guidance recalibration, comparability noise from a prior transition client, and early-stage nature of new channels (Progyny Select). Overall the positive financial performance, cash generation, and sales/retention momentum materially outweigh the transitory seasonality and execution timing risks described.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$33.00
▲(5.80% Upside)
Technical Analysis
Ownership Overview
2.88% Insiders
33.06% Mutual Funds
14.68% Other Institutional Investors
17.55% Public Companies and
Individual Investors